Sohi, Gurparneet Kaur
Farooqui, Naba
Mohan, Arjunmohan
Rajagopalan, Kamalnath Sankaran
Xing, Li
Zhu, Xiang Y.
Jordan, Kyra
Krier, James D.
Saadiq, Ishran M.
Tang, Hui
Hickson, LaTonya J.
Eirin, Alfonso
Lerman, Lilach O.
Herrmann, Sandra M. http://orcid.org/0000-0002-3700-4537
Funding for this research was provided by:
National Institute for Health Care Management Foundation (DK118120, DK109134, DK129240, HL158691, DK122734, AG062104)
Article History
Received: 6 November 2023
Accepted: 27 May 2024
First Online: 9 June 2024
Declarations
:
: The studies involving human participants were reviewed and approved by Mayo Clinic Institutional Review Board (IRB: 18-002026; “Hypoxic Preconditioning for the Improvement of the Regenerative Capacity of Adipose-derived Mesenchymal Stem Cells and Its Application in Chronic Kidney Disease due to Hypertensive Nephropathy”) in March 2018. This study adheres to the Declaration of Helsinki. Study participants provided their written informed consent to participate in this study.
: All authors consent this article for publication.
: Lilach Lerman is an advisor to AstraZeneca, CureSpec, and Ribocure Pharmaceuticals. The other authors declare no conflict of interest.